DNA methylation of the TPMT gene and azathioprine pharmacokinetics in children with very early onset inflammatory bowel disease

Thiopurine methyltransferase (TPMT) is a crucial enzyme for azathioprine biotransformation and its activity is higher in very early onset inflammatory bowel disease (VEO-IBD) patients than in adolescents with IBD (aIBD). The aims of this pharmacoepigenetic study were to evaluate differences in perip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2023-01, Vol.157, p.113901, Article 113901
Hauptverfasser: Selvestrel, Davide, Stocco, Gabriele, Aloi, Marina, Arrigo, Serena, Cardile, Sabrina, Cecchin, Erika, Congia, Mauro, Curci, Debora, Gatti, Simona, Graziano, Francesco, Langefeld, Carl D., Lucafò, Marianna, Martelossi, Stefano, Martinelli, Massimo, Pagarin, Sofia, Scarallo, Luca, Stacul, Elisabetta Francesca, Strisciuglio, Caterina, Thompson, Susan, Zuin, Giovanna, Decorti, Giuliana, Bramuzzo, Matteo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thiopurine methyltransferase (TPMT) is a crucial enzyme for azathioprine biotransformation and its activity is higher in very early onset inflammatory bowel disease (VEO-IBD) patients than in adolescents with IBD (aIBD). The aims of this pharmacoepigenetic study were to evaluate differences in peripheral blood DNA methylation of the TPMT gene and in azathioprine pharmacokinetics in patients with VEO-IBD compared to aIBD. The association of age with whole genome DNA methylation profile was evaluated in a pilot group of patients and confirmed by a meta-analysis on 3 cohorts of patients available on the public functional genomics data repository. Effects of candidate CpG sites in the TPMT gene were validated in a larger cohort using pyrosequencing. TPMT activity and azathioprine metabolites (TGN) were measured in patients’ erythrocytes by HPLC and associated with patients’ age group and TPMT DNA methylation. Whole genome DNA methylation pilot analysis, combined with the meta-analysis revealed cg22736354, located on TPMT downstream neighboring region, as the only statistically significant CpG whose methylation increases with age, resulting lower in VEO-IBD patients compared to aIBD (median 9.6% vs 12%, p = 0.029). Pyrosequencing confirmed lower cg22736354 methylation in VEO-IBD patients (median 4.0% vs 6.0%, p = 4.6 ×10−5). No differences in TPMT promoter methylation were found. Reduced cg22736354 methylation was associated with lower TGN concentrations (rho = 0.31, p = 0.01) in patients with VEO-IBD and aIBD. Methylation of cg22736354 in TPMT gene neighborhood is lower in patients with VEO-IBD and is associated with reduced azathioprine inactivation and increased TGN concentrations. [Display omitted] •The activity of TPMT, is higher in VEO-IBD than in adolescents with IBD.•DNA methylation of cg22736354 located in the TPMT gene neighborhood is lower in VEO-IBD patients.•DNA methylation of cg22736354 is associated with reduced azathioprine active metabolites.•cg22736354 methylation might regulate azathioprine pharmacokinetics in young patients with IBD.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2022.113901